Navigation Links
Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
Date:8/14/2012

d macrophages in atherosclerotic plaques. Treatment with anti-microRNA-33 in an atherosclerotic mouse model led to reduction in arterial plaque size by 35% (Rayner et al., J Clin Invest. 2011) and treatment in non-human primates increased circulating levels of HDL-C by 50%. By enhancing RCT, anti-miR-33 differs from other emerging therapeutic strategies that focus only on raising HDL-C in circulation.

About microRNAs

The discovery of microRNAs in humans during the last decade is one of the most exciting scientific breakthroughs in recent history.  microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 500 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs.  microRNA expression, or function, has been shown to be significantly altered or dysregulated in many disease states, including oncology, fibrosis and metabolic diseases. In preclinical studies, Regulus has demonstrated that modulating microRNAs can effectively regulate disease pathways and produce therapeutically beneficial effects.

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is using a mature therapeutic platform based on technology that has been developed over 20 years. The company works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS). Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strateg
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nile Therapeutics Reports 2012 Second Quarter Financial Results
2. Zenobia Therapeutics Announce A Partnership With The Alzheimers Drug Discovery Foundation
3. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
4. Echo Therapeutics Announces Second Quarter 2012 Financial Results
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
6. Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences
7. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
8. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
9. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
10. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
11. Silence Therapeutics - Admission of Shares and Board Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... und SAN DIEGO , ... Company, Ltd. (nachstehend Daiichi Sankyo) (TSE: 4568) ... ) gaben heute gemeinsam eine definitive Fusionsvereinbarung ... Aktienkapital von Ambit Biosciences für 15 US-Dollar ... und anschließenden Zusammenschluss mit einem Tochterunternehmen von ...
(Date:9/29/2014)... , September 29, 2014 The ... 21.1 billion by 2018, recording a CAGR of 8.8% ... Delivery Devices Market - Global Industry Analysis, Size, Share, ... Research, a U.S.-based market intelligence company. The ... benefit from an increasing occurrence of cardiovascular diseases, diabetic ...
(Date:9/29/2014)... PRINCETON N.J. , Sept. 29, 2014 /PRNewswire/ ... agents for medical imaging, has received a Drug ... Drug Administration for its assistance in preventing or ... being recognized for its efforts related to the ... the new drug application, submitting several post-approval supplements ...
Breaking Medicine Technology:Daiichi Sankyo wird Ambit Biosciences übernehmen 2Daiichi Sankyo wird Ambit Biosciences übernehmen 3Daiichi Sankyo wird Ambit Biosciences übernehmen 4Daiichi Sankyo wird Ambit Biosciences übernehmen 5Daiichi Sankyo wird Ambit Biosciences übernehmen 6Daiichi Sankyo wird Ambit Biosciences übernehmen 7Daiichi Sankyo wird Ambit Biosciences übernehmen 8Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 2Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 3Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 4Guerbet Receives FDA's Drug Shortage Assistance Award: Recognized for contributions to address a shortage of Ethiodol (ethiodized oil) injection 2
... RESEARCH TRIANGLE PARK, N.C., Oct. 16 Liquidia,Technologies ... founder,and University of North Carolina-Chapel Hill professor, Joseph ... DeSimone will discuss drug delivery,applications of the PRINT(TM) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20060614/CLW002LOGO ), -- ...
... went to see Dr. Peter Hersey, a medical oncologist ... was told he only had three,to six months to ... one,of the most difficult to treat forms of cancer. ... previously treated,area of his face and nothing was helping ...
Cached Medicine Technology:Targeted Nanoparticles Offer Promise in the Battle Against Cancer 2Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years 2
(Date:9/30/2014)... 2014 From October 12-15, MMS, ... the 2014 SHSMD Connections Annual Conference in San Diego, ... & Market Development (SHSMD) is proud to host the ... and communications, and strategic planning professionals in San Diego ... , The conference is a four-day event designed ...
(Date:9/30/2014)... IN (PRWEB) September 30, 2014 ... Ron Receveur encourages all persons who have received dental ... in a recent blog post. , The post, which ... with dental implants that if they don’t brush and ... same way people lose their natural teeth: the bone ...
(Date:9/30/2014)... “Biology and botany are having an ... it’s about naming rights.” , In Homeostasis: ... the Bryan William Brickner Blog, the focus is ... Health (PubMed). The post highlights five cannabinoid system ... aging with THC, the wake-inducing effects of CBD, ...
(Date:9/30/2014)... September 30, 2014 Named a ... East Longmeadow facility has officially announced that they ... that combines advanced medical technology with supportive, ... one of the only non-hospital options available in ... The primary focus of this Ventilator Program ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 American Medical ... a collaborative agreement to raise awareness about Alzheimer’s disease ... IDs for people with these brain disorders. , American ... generated by AFA to the foundation to support its ... their families. The ID bracelets and necklaces can be ...
Breaking Medicine News(10 mins):Health News:MMS, Inc. (Medical Marketing Service) to Attend the 2014 SHSMD Connections Annual Conference in October 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 3Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 2Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 3
... study by a Swedish researcher on the effects of the ... likely to occur when they have their period. The// researcher ... fluctuations causing the levels of relaxin (a hormone which relaxes ... studied for the research and it was seen that women ...
... from fatty foods that we eat. A certain amount// of cholesterol ... keep the body healthy but a high level can lead to ... a build up of small fatty lumps developing on the inside ... are at greater risk if we smoke, have high blood pressure ...
... a press release the Ministry of Health has indicated the current ... on Dengue// the Ministry has confirmed reports of 9453 cases ... upto 12 .30 hrs. ,In Delhi and NCR - ... of 2872 cases and 59 deaths have been reported from Delhi, ...
... access to a high-profile detainee at Guantanamo Bay, Cuba, ... secrets" whose revelation could "cause extremely grave damage", the ... at secret CIA prisons must not be allowed to ... even to their lawyers, the Post reported.,A lawyer at ...
... medical problems and surgeries in space before astronauts start moving ... a person develops a problem say, in Mars? He or ... time simply because it takes over three years to reach ... little difference in the dose of general anesthesia needed to ...
... industry which has been simmering in the trans-fat controversy for ... their sticky ally- the hydrogenated// vegetable oils! This is perhaps ... & Spencer, Asda, Sainsbury’s and Tesco have already communicated their ... British Medical Journal has urged the Government to bring in ...
Cached Medicine News:Health News:Researchers explore medicine in space 2Health News:Researchers explore medicine in space 3
Full Handle Laseredge Crescent Blade Knife, angled double bevel. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 45 blade. Blade tip dimension: 8.9 mm x 1.9 mm x 1.9 mm....
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 3 mm x 1.0 mm x 3.0 mm....
Medicine Products: